Weekly Neurology Deep Dive - A review of recent impactful publications in the field of Neurology

This umbrella review evaluates the clinical efficacy and safety of two recently approved anti-amyloid antibodies, lecanemab and donanemab, for treating early-stage Alzheimer’s disease. By synthesizing data from eleven high-quality systematic reviews and meta-analyses, the authors conclude that these drugs successfully reduce brain amyloid burden and provide a statistically significant slowing of cognitive decline. However, the text highlights a critical concern: the observed cognitive benefits often fall below established clinically meaningful thresholds, suggesting that patients might not perceive a significant improvement in daily life. Furthermore, both treatments are associated with an increased risk of amyloid-related imaging abnormalities (ARIA), such as brain edema and hemorrhage, particularly in ApoEε4 gene carriers. Consequently, the source emphasizes that prescribing these therapies requires rigorous patient selection, careful monitoring through regular MRIs, and transparent communication regarding the modest expected outcomes. Ultimately, while these antibodies represent a significant pharmacological shift in dementia care, their benefits must be carefully weighed against potential safety risks and high financial costs.

This paper provides a comprehensive clinical framework for the examination and localization of eye movement disorders, emphasizing that the systematic bedside assessment serves as the primary tool for anatomical diagnosis. By distinguishing between supranuclear, nuclear, and infranuclear lesions, clinicians can categorize ocular motor dysfunction based on how specific eye movements, such as saccades or the vestibulo-ocular reflex, are impacted. The sources outline essential quantitative bedside tools—including prism cover tests and the HINTS battery—to differentiate between vascular, inflammatory, and degenerative causes. Detailed profiles of various conditions are provided, ranging from cranial nerve palsies and brainstem stroke syndromes to complex neuromuscular junction disorders like myasthenia gravis. Ultimately, the text illustrates how specific findings, such as pupillary involvement or fatigability, help narrow a wide differential into a precise neurological or structural diagnosis.

This comprehensive review examines the evolution and clinical potential of liquid biopsy, a non-invasive diagnostic method that analyzes biomarkers within bodily fluids. The text classifies primary biomarkers such as circulating tumor DNA, intact tumor cells, and extracellular vesicles, while detailing the high-sensitivity technologies like digital PCR and next-generation sequencing used to detect them. In oncology, the authors highlight how these tools facilitate early cancer screening, the prediction of therapeutic responses, and the real-time monitoring of minimal residual disease or drug resistance. The scope extends beyond cancer to include applications in reproductive medicine, organ transplantation, and neurological disorders. Finally, the researchers address current implementation hurdles, such as the need for standardized protocols, and identify artificial intelligence as a key driver for future clinical integration.

This systematic review and meta-analysis evaluates the effectiveness and safety of therapeutic plasma exchange (TPE) for treating autoimmune neurological diseases (ANDs). By analyzing 38 studies involving 2,199 patients, the research indicates that TPE leads to a high rate of clinical improvement across various conditions, including Guillain-Barré syndrome and myasthenia gravis. While age appears to influence the success rate—with younger patients showing better responses than those over 60—geographic region and specific disease types do not show statistically significant differences in efficacy. The study finds an all-cause hospital mortality rate of 4%, though these deaths are largely attributed to the progression of the underlying disease rather than the procedure itself. Common but manageable adverse events identified include hypotension, coagulation disorders, and infections. Ultimately, the authors conclude that TPE is a safe and beneficial intervention, though they call for more rigorous, multicenter trials to refine treatment protocols.

Parsonage-Turner syndrome, also known as neuralgic amyotrophy, is a frequently misdiagnosed peripheral nerve disorder characterized by sudden, intense shoulder pain followed by muscle weakness and atrophy. While historically considered a rare and temporary condition, contemporary research reveals it is far more prevalent and can cause long-term disability and persistent fatigue. The condition is believed to be immune-mediated, often triggered by infections, physical trauma, or genetic predispositions, specifically involving the SEPT9 mutation. Diagnosis is primarily clinical but is increasingly supported by advanced imaging, such as ultrasound and MRI, which can detect unique nerve constrictions. While corticosteroids may offer early pain relief, long-term management focuses on specialized rehabilitation and, in severe cases, surgical intervention to address structural nerve damage. These updated insights emphasize that early recognition is vital for improving patient outcomes and preventing chronic functional loss.
This episode is based on a paper written exclusively for the Weekly Neurology Deep Dive Podcast by Amer A. Ghavanini MD PhD FRCPC.